Notice of Extraordinary General Meeting of Episurf Medical AB (publ)

Episurf Medical has convened an Extraordinary General Meeting for 10 February 2026 to seek shareholder approval for the proposed acquisition of Goldcup 38658 AB (holding a portfolio of properties and bonds) for a preliminary maximum consideration of SEK 1,147 million. To enable the transaction the Board proposes amendments to the articles to permit real estate activities and to raise share capital limits (from SEK 15.0–60.0m to SEK 23.6–94.4m) and share counts (from 1.5–6.0bn to 2.36–9.44bn), plus an authorisation to issue B‑shares, convertibles and warrants (with or without pre‑emption rights) to complete the acquisition. The meeting also proposes board changes (Christian Krüeger to leave; proposal to elect Jens Andersson, bringing the board to three members) and notes the company has 1,659,761,378 shares outstanding (total votes 1,660,708,092).

Analysis

Market Structure: Episurf’s proposed SEK 1,147m Acquisition of property-and-bond assets and the simultaneous articles overhaul converts a med‑tech equity into a hybrid investment/real‑estate vehicle. Direct winners: seller/recipients of consideration and bondholders of the acquired portfolio; losers: existing Episurf shareholders facing potential large dilution (authorised shares cap could rise ~5.7x from 1.66bn to 9.44bn). This is unlikely to change pricing power in med‑tech but will reclassify Episurf into small‑cap Swedish real estate/asset manager peer set.

Risk Assessment: Key tail risks include shareholder rejection at the EGM (requires 2/3 votes) or a related‑party/insider transaction investigation; financing risk if equity issuance is priced below market causing >30–50% dilution shock. Time buckets: immediate (days) — EGM outcome on 10 Feb 2026; short (weeks) — issuance mechanics and pricing; long (quarters) — NAV recognition of property/bond portfolio and investor base rotation. Hidden dependency: potential common ownership/relationship between sellers (Frusipe/Goldcup) and insiders, which could signal self‑dealing.

Trade Implications: If EGM passes, expect near‑term sell pressure. Direct plays: establish a tactical 3–5% short position in Episurf equity (or buy puts) on confirmation of approval, size to portfolio liquidity and borrow cost; hedge with a 1–2% long in high‑quality Swedish REITs (e.g., CTM — Castellum) to capture sector re‑rating. Options: buy a 3–6 month put spread on Episurf (buy 30–40% OTM put, sell deeper OTM) to cap premium and exploit post‑approval volatility.

Contrarian Angles: Consensus may underprice governance risk — management replacing med‑tech operations with real estate often destroys shareholder returns (histor precedent: small cap pivots that triggered multiple compressions of 40–70%). If EGM is rejected, episodic short squeeze upside of 25–50% is possible; monitor vote disclosure thresholds and any insider lock‑ups. Unintended consequence: failure to consummate acquisition after authorisations could leave Episurf with expanded charter and shareholder distrust, limiting future capital raises.

Key Decisions for Investors

• If EGM votes in favour (>=66.7%): initiate a 3–5% portfolio short of Episurf equity (name: Episurf Medical) or buy 3–6 month put spread sized for maximum loss = 2% of portfolio; target gain 30–60% if dilution/pricing shock occurs; place stop at 15% adverse move.
• Simultaneously allocate 1–2% long to CTM (Castellum, ticker CTM) to express a rotation into established Swedish RE assets versus opportunistic small‑cap property holders; hold 3–9 months to capture sector rerating.
• If EGM vote fails: cover shorts and consider a 2% opportunistic long in Episurf for a potential 25–50% rebound within 30 days; exit if management announces follow‑up financing within 60 days that implies >20% new‑issue dilution.
• Do not participate in any Episurf capital raise unless pricing is at a premium to pre‑announcement market cap or dilution <20%; require transparent third‑party asset valuations and no related‑party links (investigate Frusipe/Goldcup ownership structure within 7 days).